Exploiting ETH Zurich research, Micreos is working on a clinical platform that enables the targeted killing of unwanted bacteria only.
Micreos, a Netherlands-based endolysin platform developer using research from ETH Zurich, raised €32m ($37.5m) in funding from undisclosed investors yesterday.
Micreos is working on technology that enables the targeted killing of unwanted bacteria only. The approach relies on endolysins – hydrolytic enzymes that can attack specific bacteria while leaving the remainder of the microbiome intact and thus present an advantage over antibiotics.
The technology was developed together with ETH Zurich, although Micreos is not a spinout of the institute.
It…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
